NASDAQ:HPTX - Horizon Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$45.99
Today's RangeN/A
52-Week Range$20.23 - $46.96
VolumeN/A
Average Volume786,899 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive HPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HPTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:HPTX
CUSIP44915N10
WebN/A
Phone+1-650-7457802

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Horizon Therapeutics (NASDAQ:HPTX) Frequently Asked Questions

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HPTX."

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics Inc (NASDAQ:HPTX) released its quarterly earnings results on Thursday, February, 26th. The biopharmaceutical company reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.67. The biopharmaceutical company earned $30.80 million during the quarter, compared to the consensus estimate of $24.60 million. The business's quarterly revenue was up 65.6% on a year-over-year basis. View Horizon Therapeutics' Earnings History.

Has Horizon Therapeutics been receiving favorable news coverage?

News stories about HPTX stock have been trending somewhat negative on Tuesday, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Horizon Therapeutics earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.

What other stocks do shareholders of Horizon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics investors own include Mallinckrodt (MNK), Cigna (CI), Cynosure (CYNO), Wright Medical Group (WMGI), TG Therapeutics (TGTX), U.S. Physical Therapy (USPH), Iqvia (IQV), Health Net (HNT), GW Pharmaceuticals PLC- (GWPH) and Infinity Pharmaceuticals (INFI).

How do I buy shares of Horizon Therapeutics?

Shares of HPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 2000 Sierra Point Pkwy Ste 400, BRISBANE, CA 94005-1849, United States. The biopharmaceutical company can be reached via phone at +1-650-7457802.


MarketBeat Community Rating for Horizon Therapeutics (NASDAQ HPTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel